Zamosc

• REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vessels Ended recruitment
  2023-506924-94-00 5 2023-02-28 Cardiovascular disease
• A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely … Ended recruitment
  2023-504719-34-00 5 2023-02-21 Moderate to Severly Active Ulcerative Colitis
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t … Ended recruitment
  2023-504737-41-00 5 2022-06-10 Moderately to Severely Active Crohn's Disease
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A study to compare how safe and well tolerated study drug Abelacimab (MAA868) is compared to another drug called Rivaroxaban in patients wit … Ended recruitment
  2023-509066-38-00 4 2021-04-16 Atrial Fibrillation
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended recruitment
  2022-502841-91-00 5 2020-08-12 Crohn’s Disease
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended recruitment
  2023-507657-15-00 5 2018-09-13 Ulcerative Colitis
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504736-18-00 10 2018-07-26 Moderately to Severely Active Crohn's Disease
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 Rheumatoid Arthritis
• A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi … Ended
  2023-506664-14-00 5 2024-10-24 Rheumatoid Arthritis
• Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly … Ended
  2023-508924-36-00 5 2024-08-20 Type 2 diabetes mellitus (T2DM)
• REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete … Ended
  2022-502677-42-00 5 2024-07-24 Type 2 diabetes
• A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit … Ended
  2024-511408-18-00 5 2024-07-15 Type 2 Diabetes inadequately controlled with dapagliflozin with or wit
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended
  2022-502778-18-00 5 2023-11-17 ulcerative colitis
• A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended
  2022-502393-16-00 5 2023-09-06 Moderately to Severely Active Ulcerative Colitis
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis

Showing 49–72 of 81 trials